Genome-wide association study in Brazil identifies risk factor-adjusted genetic susceptibility to pulmonary tuberculosis with cell-specific gene expression effects

Short title: Brazil PTB GWAS

Kimberly A Dill-McFarland[1][*][†], Bruno B Andrade[2,3][*][†], Marina C Figueiredo[4], Alice M S Andrade[2,3], Francys Avendaño-Rangel[2,3], Marcelo Cordeiro-Santos[5,6], Afrânio L Kritski[7], Valeria C Rolla[8], Juan M Cubillos-Angulo[2], Spyros A Kalams[4,9], Josh D Simmons[4], Jared M Oakes[9], Jonathan Peña Avila[10], Helder I Nakaya[10,11], Rama D Gangula[4], Peter F Rebeiro[4], Gustavo Amorim[12], Simon A Mallal[4], Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil Consortium, Timothy R Sterling[4][†], Thomas R Hawn[1][†]

[1] Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA;
[2] Laboratório de Pesquisa Clínica e Translacional, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz (FIOCRUZ), Salvador, BA, Brazil;
[3] Instituto de Pesquisa Clínica e Translacional, Medicina Zarns, Clariens Educação, Salvador, BA, Brazil;
[4] Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA;
[5] Fundação de Medicina Tropical Dr. Heitor Vieira Dourado do Amazonas, Manaus, AM, Brazil;
[6] Curso de Medicina, Universidade do Estado do Amazonas (UEA), Manaus, AM, Brazil;
[7] Programa Acadêmico de Tuberculose da Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil;
[8] Laboratório de Pesquisa Clínica em Micobacteriose, Instituto Nacional de Infectologia Evandro Chagas (FIOCRUZ), Rio de Janeiro, RJ, Brazil;
[9] Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA;
[10] Department of Clinical and Toxicological Analyses, University of São Paulo, São Paulo, SP, Brazil;
[11] Hospital Israelita Albert Einstein, São Paulo, SP, Brazil;
[12] Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA

[*] Co-first authors
[†] Co-corresponding authors

Corresponding authors
Kimberly A Dill-McFarland, kadm@uw.edu
Bruno B Andrade, Bruno.andrade@fiocruz.br
Timothy R Sterling, timothy.sterling@vumc.org
Thomas R Hawn, thawn@uw.edu

ABSTRACT

Although genetic factors contribute to tuberculosis (TB) risk, no cross-population causal variants have been identified by genome-wide association studies (GWAS). Here, we utilized low-pass whole genome sequencing (lpWGS) with imputation plus detailed epidemiologic risk factors and single-cell expression quantitative loci (sceQTL) to address prior GWAS limitations. Using 947 pulmonary tuberculosis (PTB) cases and 1807 close contact controls in the Regional Prospective Observational Research in TB (RePORT) study in Brazil, we estimated PTB heritability to be 47.7%. We identified 19 SNPs associated with PTB (P<5E-8) after adjustment for major risk factors (HIV, diabetes, smoking). Seven of these SNPs were associated with peripheral blood cell-specific sceQTLs in controls. Specifically, SNPs cis to transcription factors ZNF717 and MAML3 were associated with PTB disease and gene expression in monocytes, T cells, or B cells. Overall, this study utilized lpWGS, in-depth epidemiology, and single-cell analyses to detect population-specific genetic risk factors for PTB in Brazil.

INTRODUCTION

Multiple studies over the past 50 years suggest that host genetics regulate susceptibility to tuberculosis (TB), yet the major causal genes remain largely unknown [1,2]. This gap in knowledge regarding "missing heritability" is exemplified by the lack of reproducible findings among genome-wide association studies (GWAS) of TB in several countries [3–12]. The reasons for missing heritability in TB GWAS are multifactorial. Differences in underlying population genetics, population-specific genetic risk factors, genotyping platforms, imputation reference panels, *Mycobacterium tuberculosis* (Mtb) strains, and a lack of adjustment for clinical TB risk factors

may hinder the reproducibility of TB GWAS results. In addition, prior GWAS often lack direct

experimental connections of associated genetic variants to functional outcomes that may

impact TB outcomes. Designing studies to address these limitations may foster the discovery of

the missing genetic regulators of susceptibility to TB.

Genotyping methods for GWAS studies continue to evolve to better measure high-confidence

genetic variants within and across populations. High-pass whole genome sequencing (hpWGS)

with at least 30X coverage is the gold-standard to comprehensively define genetic variation that

may be population- and/or disease-specific. However, due to budgetary constraints, alternative

methods are more often employed. Single nucleotide polymorphism (SNP) arrays with or

without imputation are the most common genotyping platforms. These platforms were used in

all prior TB GWAS, but they rely on pre-selected SNPs based on previously genetically

characterized populations. Low-pass WGS (lpWGS, ≤ 1X coverage), along with recent advances

in imputation, offers a cost-effective alternative to capture more population- and disease-

specific variation compared to SNP arrays [13]. In addition, while the discovery of statistically

significant SNPs remains the primary goal of GWAS, evidence of the functional effects of these

SNPs is needed to fully elucidate their role in TB pathogenesis. In some studies, database-

derived expression quantitative trail loci (eQTL) provide evidence of SNP function, but current

transcriptomic databases are limited by the small number of cell types and/or human

populations available for comparison to GWAS studies. Single-cell eQTL data in the same

population as a GWAS could address this gap and expand the functional assessment of

candidate GWAS SNPs.

In addition, precise phenotyping of traits is an essential feature of genetic studies. For TB cases,

genetic signals may be obscured by other strong TB risk factors including HIV, diabetes mellitus

(DM), smoking, alcohol consumption, malnutrition, and others. In addition, control

misclassification can occur if there is insufficient Mtb exposure and/or follow-up duration

among controls. Previous TB GWAS mainly focused on pulmonary TB (PTB) in HIV-negative

populations with adjustments for age, sex, and ancestry but not other risk factors such as DM

and smoking [3-12]. The method to control for potential confounders is most often a matched

case-control design while an alternative full cohort, covariate-adjusted method is

underexplored despite providing more statistical power.

To address some of the methodologic limitations of prior TB GWAS, we prospectively enrolled

PTB cases and their close contact in the Regional Prospective Observational Research in TB

(RePORT) study in Brazil, genotyped SNPs by lpWGS with imputation, and performed both full

cohort covariate-adjusted and case-control analyses. We also assessed the functional relevance

of candidate SNPs through eQTL analysis in a peripheral blood mononuclear cell (PBMC) single-

cell RNA-seq substudy in RePORT-Brazil.

METHODS

Cohort. From 2015 to 2019, culture-confirmed adult pulmonary tuberculosis (PTB) patients

were recruited at study clinics in Rio de Janeiro, Manaus, and Salvador as part of the Regional

Prospective Observational Research in TB (RePORT) study in Brazil. Full details were reported

previously [14]. Briefly, PTB cases were confirmed by positive *Mycobacterium tuberculosis* sputum

culture at enrollment (N = 1,060, **Figure S1**). Close contacts of PTB patients were then recruited

using cumulative density sampling under the criteria of > 4 hrs/wk of contact with the index PTB

cases within the past 6 months (N = 1,839). Controls were defined as close contacts with

normal chest radiograph at enrollment and no symptoms for 24 months of follow-up.

Additional radiograph tests and sputum were only performed when contacts presented with

symptoms during the course of the study. Close contacts who progressed to active PTB during

this time were classified as progressors (N = 25) and excluded from the GWAS. This study was

approved by the institutional review boards of the study sites in Rio de Janiero (Instituto

Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz [FIOCRUZ], Faculdade de

Medicina e Centro Municipal de Saúde de Duque de Caxias, Universidade Federal do Rio De

Janeiro, Secretaria Municipal de Saúde do Rio De Janeiro e Clínica Da Família Rinaldo

Delamare), Salvador (Instituto Brasileiro Para Investigação da Tuberculose [IBIT], Fundação José

Silveira), and Manaus (Fundação de Medicina Tropical Dr. Heitor Vieira Dourado) as well as

Vanderbilt University Medical Center. Written informed consent was obtained from all

participants.

Case-control subset. Among the 2,754 pass-filter individuals (see below), 819 individuals (241

controls, 578 PTB cases) were included in a case-control subset in which all were HIV-

seronegative and without diabetes mellitus (DM). DM was self-reported for controls and

defined by HbA1C at enrollment < 6.5 for cases. In addition, controls were IGRA-positive at

enrollment, received < 30 days of any treatment for tuberculosis infection during the course of

the study, and had ≥ 12 months of follow-up during which they did not develop active PTB.

Treatments included isoniazid or rifampin monotherapy.

Sample collection and DNA library preparation. At enrollment, whole blood was collected in

EDTA tubes, aliquoted, and immediately frozen at −80 °C. DNA was extracted from 100 µl of

whole blood using the DNeasy Blood and Tissue Kit (Qiagen) following the manufacturer's

protocol with an additional final centrifugation to maximize DNA recovery. DNA was quantified

using Qubit Fluorometer (Thermo Fisher) and aliquoted in 96 well plates to 10 ul at 100 ng/ul.

Libraries were prepared using the Twist Biosciences kit (P/N: 104207) following a miniaturized

version of the manufacturers protocol and quantified using Qubit. Pool quality was assessed

using the Agilent Bioanalyzer and quantified using a qPCR-based method with the KAPA Library

Quantification Kit (P/N: KK4873) and the QuantStudio 12K instrument. Prepared DNA library

pools were pooled for sequencing in equimolar ratios based on qPCR.

Low-pass sequencing and genotype calls. In total, 2791 participants were sequenced using

Illumina low-pass whole genome sequencing (lpWGS) at 1-2X coverage at Vanderbilt University

Medical Center Technologies for Advanced Genomics (VANTAGE). DNA library pools were

subjected to cluster generation using the NovaSeq 6000 System, following the manufacturer's

protocols. Sequencing was performing using 150 bp paired-end reads on the NovaSeq 6000

platform targeting 10 million reads per sample (1-2X genomic coverage). Raw sequencing data

(FASTQ) was subjected to quality control analysis, including read quality assessment. Real Time

Analysis Software (RTA) and NovaSeq Control Software (NCS) (1.8.0; Illumina) were used for

base calling. MultiQC (v1.7; Illumina) was used for data quality assessments. Single nucleotide

polymorphisms (SNPs) were called using Illumina DRAGEN Germline v4.0.3 with default low-

pass parameters in Illumina BaseSpace. Genotypes were then imputed using Illumina DRAGEN

Imputation v4.0.3, which implemented GLIMPSE [13] against the 1000 Genomes Project Phase 3

[15] IRPv1 autosomal SNP reference panel (N = 2,489). Imputation resulted in 49.5 million

autosomal SNPs, of which 31.1 million (63%) had an imputation score > 0.6. Genotypes were

further processed using PLINK2 [16,17] and R v4.4.0 [18]. SNPs on X and Y chromosomes were not

included in the analysis. In addition, 3 samples (2 cases, 1 contact) failed quality controls prior

to imputation and were not included in analyses.

Ancestry and kinship. Imputed genotypes were filtered by imputation score > 0.6, minor allele

frequency (MAF) > 1%, and sliding window linkage disequilibrium (LD) with a 500 kb window, 1

kb slide, and maximum r^2 of 0.2 using PLINK2. With the resulting 12.6 million genotypes,

identity by descent was calculated using the Robust KING method [19] in SNPRelate [20] and

ancestry principal components (PCs) were estimated using PC-AiR [19,21] in GENESIS [22]. Kinship

was then calculated using PC-Relate [23] with 2 ancestry PCs and a training set of the 1,554

unrelated individuals defined by PC-AiR. Sample pairs with high relatedness (kinship > 0.9) were

further assessed and determined to be twins (N = 5 pairs), siblings (N = 1), duplicate samples (N

= 5), or unrelated/unknown (N = 2). The first chronological sample was retained for duplicates,

and high-kinship unrelated/unknown pairs were removed from analysis. This resulted in 2,754

individuals for GWAS analyses (1,807 controls, 947 PTB cases).

Pass filter samples were compared to 1000 Genomes Project Phase 3 [15] (N = 2,548) using

principal component analysis (PCA). RePORT imputed genotypes were filtered to imputation

score > 0.6, MAF > 5%, Hardy-Weinberg Equilibrium (HWE) P > 1E-6, 0% missingness, and > 60%

concordance with high-pass WGS (see *Genotype validation*). Overlapping filtered RePORT and

1000 Genomes genotypes were then filtered to remove AT and CG SNPs, which are more prone

to sequencing error, and LD filtered using a sliding window of 100 kb, 1 kb slide, and r^2

threshold of 0.1. Finally, genotypes were filtered to MAF > 10% in the combined dataset. Using

these 96,426 SNPs, PCs were calculated using PLINK2, and RePORT participant self-reported

race was compared to 1000 Genomes Super Populations.

GWAS model fitting. From the 12.6 million genotypes used for kinship, 10,000 random

positions were selected for model fitting. Mixed effects logistic regression was performed to

test genotype associations with PTB cases (1) vs close-contact controls (0) (**Table S1**).

Participants predominantly identified as brown (57%), black (22%), or white (20%), which most

closely corresponded to 1000 Genomes [15] admixed American, African, and European Super

Population ancestry groups, respectively, though significant admixing was apparent (**Figure**

S2A,B). Ancestry PCs were progressively added to the base GWAS model and assessed for total

variation explained as well as model fit by Akaike Information Criterion (AIC). A covariate was

retained if it significantly improved model fit in its univariate model and its removal worsened

model fit in its leave-one-out model ($|\Delta AIC| > 8$). The first two ancestry PCs were included in

the final model as they explained the most variation (PC ≥ 1%) (**Figure S2C**) and improved

model fit for the majority of SNPs as indicated by reduced AIC compared to models with one

fewer PCs (**Figure S2D**). Next, kinship was added to the 2 PC logistic model as a pairwise

covariance random effect and tested with GMMAT [24]. While kinship did not improve model fit

(**Figure S2E**), the cohort contained 371 first-degree relationships (kinship > 0.5), including

several twin pairs (**Figure S2F**). Thus, kinship was retained in the model to account for this

relatedness.

Finally, additional clinical covariates age and sex as well as PTB risk covariates smoking, HIV

status, and diabetes mellitus (DM) (self-reported for controls, enrollment HbA1C > 6.5 for

cases) were assessed. Each covariate was assessed in univariate models (e.g. 2PC kinship model

+ one covariate, **Figure S2G**) and leave-one-out models (e.g. 2 PC kinship model + all covariates

except one, **Figure S2H**). Smoking was classified as past/current vs never as there were no

significant differences between past and current smokers in a univariate model (**Table S1**, P >

0.3). All covariates except age significantly improved model fit when added in univariate models

and worsened model fit when removed in leave-one-out models (**Table S1**). Age initially

worsened model fit when added to the simpler model but had no significant effect when

removed from the more complex model ($|\Delta AIC| < 8$). Thus, age was retained in the final model

to facilitate comparisons to previous GWAS studies that commonly corrected for age. This

resulted in the full cohort model

$$(1)\ logit(\text{PTB} = 1|X, u) = \alpha + \beta_1 \text{SNP}_i + \beta_2 \text{PC1} + \beta_3 \text{PC2} + \beta_4 \text{sex} + \beta_5 \text{age} +$$

$$\beta_6 \text{smoke} + \beta_7 \text{HIV} + \beta_8 \text{DM} + u,$$

$$u \sim \mathcal{N}\left(0, \sigma_g^2 K\right)$$

where logit(P(TB=1|X, u)) is the log-odds of PTB disease given the covariates X and random

effects u, α is the intercept, β are the coefficients of main effects (SNP) and covariates (ancestry

PCs, clinical covariates, PTB risk covariates), and u is the random effects with covariance

structure determined by genetic kinship (K). The case-control cohort was modeled for a

comparable model removing PTB risk covariates (HIV, DM) that were absent in this subset.

GWAS statistics. The full dataset imputed 49.5 million genotypes were filtered for imputation

score > 0.6, MAF > 5%, HWE P > 1E-6 (calculated on controls only), and 0% missingness. This

resulted in 6,944,453 genotype positions for analysis. The full cohort was modeled with

adjustment for ancestry, kinship, clinical, and PTB risk covariates as in equation (1), and the

case-control subset with this model without HIV and DM as person living with HIV and/or DM

were excluded from this analysis. Both cohorts were additionally analyzed with a simplified

model without all three PTB risk covariates (smoking, HIV, DM) to compare with previous GWAS

studies.

The rationale for the full cohort analysis was to maximize sample size and potential statistical

power while adjusting for covariates that could decrease precision without fully addressing

confounding bias. The rationale for the case-control subset was to optimize case and control

selection to exclude variability introduced by risk factors known to be associated with PTB

disease (e.g. HIV, DM). The case-control design helped improve statistical efficiency for

estimating the causal effect within and across strata of balanced characteristics (relying on

discordant pairs to be informative) and more powerfully limited the confounding bias for

important *a priori*-identified confounders. Though the case-control design lent itself to

estimating a causal effect less prone to bias and more likely to be internally valid, statistical

power was reduced relative to the full cohort sample size. The merits of the full cohort analysis

(improved power to detect small effects) and case-control design (improved internal validity to

detect unbiased causal effects) are, therefore, complementary instead of redundant.

All genotypes were scored using GMMAT (glmm.score) [24] in the full and case-control cohorts

separately. Genotypes with a score $P < 1E-4$ were then fit in the full GLMMkin model. In

addition, all full cohort selected genotypes were also run in the case-control subset. Significant

SNPs were defined at $P < 5E-8$ and suggestive SNPs at $P < 5E-5$. Lower MAF genotypes (1 - 5%)

were then selected within 10 kb of significant SNPs and tested with the same models described

above as well as assessed for linkage disequilibrium (LD) with significant SNPs in the region.

Significant SNPs were also tested for associations with clinical and PTB risk covariates by

modeling sex, age, smoking, HIV, or DM as outcomes in place of PTB status while retaining all

other covariates. Finally, significant SNPs were cis-mapped to genes within 50 kb. Gene

enrichment was performed against Broad MSigDB [25] Hallmark, canonical pathways, and gene

ontology using iterative hypergeometric enrichment in SEARchways [26] to account for SNPs with

multiple gene annotations.

The overall heritability of PTB progression was calculated using Genome-wide Complex Trait

Analysis (GCTA [27]) with a genetic relationship matrix (GRM) and restricted maximum likelihood

(REML [28]) calculated from concordant SNPs in 1020 unrelated individuals from the full cohort

(594 controls, 426 cases, GRM < 0.05). Prevalence was estimated as the mean PTB prevalence

during the recruitment period (2025-2019) in RePORT participating Brazilian states (Amazonas,

Bahia, Rio de Janeiro) according to the Pan American Health Organization (57.07 cases per

100,000 population) [29]. Models were corrected for covariates as in the full cohort (ancestry PCs,

sex, age, smoking, HIV, DM) as well as without PTB risk covariates for comparison.

Genotype validation by high-pass sequencing. To validate imputed genotypes, a random

subset of individuals (25 controls, 25 cases) was re-sequenced with 30X genome coverage at

VANTAGE. DNA library pools were subjected to cluster generation using the NovaSeq X Plus

System, following the manufacturer's protocols. Sequencing was performed using 150 bp

paired-end sequencing on the NovaSeq X Plus platform targeting 350 - 400 million reads per

sample (30X genomic coverage). Raw sequencing data (FASTQ) was quality assessed, and bases

were called as for low-pass sequencing. Sequences were then cleaned using SEAsnake [30]

(maximum ambiguous bases = 1, minimum length = 15, minimum quality = 30, 5-prime

trimming = 10 bp, adapters = Illumina universal). Sequences were aligned with STAR (2.7.9a)[31]

against the human genome GRCh38, release 112 and SNPs were called with bcftools mpileup

v1.14 [32] with a minimum base quality of 20 and a minimum mapping quality of 30.

Significant GWAS SNPs were also compared to SNP manifests for 19 arrays used in prior TB

GWAS studies. UCSC LiftOver [33] was used to convert this study's hg38 genomic locations to

older genome versions (hg37, hg36, hg35) for comparisons. Only 6 of the 19 significant

concordant SNPs were present on one or more arrays. The most overlap was found with the

custom LIMAArray (4 SNPs), which was designed for a Peruvian population [3].

Single-cell RNA sequencing. Single-cell RNA-sequencing (scRNAseq) was performed on

peripheral blood mononuclear cells (PBMC) from a subset of close contacts. This included 25

controls who progressed to PTB and 33 sex-, age- (+/- 5 yrs), and interferon gamma release

assay (IGRA)-matched controls from RePORT-Brazil. PBMC were thawed, washed twice with

phosphate buffered saline (PBS), and resuspended at 10E6 cells/100 ml in RPMI (MT10040CV

from Mediatech/Corning) with 10% human serum. Cells were rested 2 hours, CD40 blocking

antibody was added for 15 minutes (1:200 dilution, 0.5 ul), and then CD40L (diluted 1:10) was

added. Cells were incubated overnight, washed with PBS, and then washed with cell staining

buffer. Cells were resuspended in 50 ml of staining buffer and 5ml of the Fc blocking agent

Human true stain FcX (cat#422302, Biolegend) and placed on ice for 10 minutes. Cells were

hash-tagged using one microliter of TotalSeq-C Human Universal Cocktail (Biolegend) per

sample and incubated on ice for a further 30 minutes. Cells were then washed three times and

resuspended in staining buffer. A 137 Cite-seq C antibody (cat#399905, Biolegend) panel was

prepared as per the manufacturer's guidelines. For pools of 4-5 samples, 50ml of the antibody

panel was added, and cells were incubated on ice for 30 minutes. Cells were washed three

times with PBS with 2% BSA and resuspended in PBS with 1% BSA. Approximately 8,000 cells

per individual were provided to the VANTAGE sequencing core. Libraries were created following

the 10X Genomics standard protocol (3-prime version 4), and sequencing was performed on an

Illumina NovaSeq 6000 at VANTAGE.

Raw sequences (FASTQ) were processed using 10x Genomics Cell Ranger Multi v9.0.0 using 10x

Genomics Cloud Analysis [34]. Poor-quality cells, doublets, and high mitochondrial cells (> 10%)

were removed. Genes not expressed in at least 150 cells were removed. Imputation was

applied to the concatenated count matrix using Adaptively-thresholded Low Rank

Approximation (ALRA) [35] in R v4.3.3 [18]. Further data cleaning and annotation was performed

using python v3.10.16. A consensus set of highly variable genes (HVG, n = 5000) were calculated

on the imputed counts across project batches. Principal component analysis (PCA, n = 30) was

done. The PCA result was submitted to the Harmony algorithm for integration (theta = 2) [36]. K-

nearest neighbors (kNN, n = 30) were found using the Harmony components. Leiden clustering

(resolution = 3) was used to partition the kNN graph. Cell clusters were split into three groups: T

and natural killer (NK) cells, myeloid cells, and B cells. Each subset was then analyzed separately

by HVG, PCA, Harmony, kNN, and Leiden clustering. Uniform Manifold Approximation and

Projection (UMAP) was used for visualization. Leiden clusters were annotated according to

canonical marker expression profiles. Subset-specific HVG n-genes were set as follows: T/NK (n

= 4000), myeloid (n = 2500), and B (n = 2000). Harmony theta was set as follows: T/NK (n = 4),

myeloid (n = 4), and B (n = 2). Leiden resolution was set as follows: T/NK = 2.5, myeloid = 1, and

B = 1.

Single-cell expression quantitative loci (sceQTL). In total, 58 participants with both scRNAseq

and GWAS data were selected. A subset of participants (N = 25) were progressors to PTB and

not included in the original GWAS; thus, ancestry PCs and kinship were re-calculated for this

combined subset as described above. Kinship values were highly correlated across controls

processed in this subset versus the full cohort (Pearson R = 0.998, P < 2.2E-16). sceQTL analysis

was performed in R v4.4.2 [18]. Single-cell data (543,229 cells) were pseudo-bulked using Seurat

v5.1.0 [37], and the 32 cell types were processed independently. Counts were filtered to protein-

coding genes, those with expression in at least 3 samples, trimmed mean of means (TMM)

normalized, and transformed to log2 counts per million (CPM) with gene-level quality weights

using edgeR [38] and limma [39,40]. This resulted in 7,297 to 13,029 genes for analysis per cell type.

SNP data were filtered to overlapping single-cell participants and GWAS-significant SNPs that

were annotated to at least one protein-coding gene, concordant with high-pass data, and

expressed in at least one cell type in single-cell data. This yielded 9 SNPs annotated to 8

protein-coding genes, which resulted in 12 unique gene-SNP pairs. These pairs were modeled

against gene expression in the 32 single-cell RNAseq cell types using a kimma [41] additive model.

Covariate inclusion was assessed in univariate and leave-one-out models as with GWAS model

fitting (**Table S2**), which resulted in a final sceQTL model without clinical or PTB risk covariates

(**Figure S3**).

339
$$(2)\ expression = \ \alpha + \beta_1 \text{SNP}_i + \beta_2 \text{PC1} + \beta_3 \text{PC2} + u,$$

$$u \sim \mathcal{N}\left(0, \sigma_g^2 K\right)$$

where components are as described in equation (1), except expression is the pseudo-bulk gene

expression per individual within cell type. FDR correction was applied within cell type across

SNPs annotated to the same gene. Significance was determined at FDR < 0.05. Sensitivity

analyses were performed including covariates relevant to GWAS models (sex, age, smoking, DM

as in equation (1)). Dominant models were also assessed for SNPs with a measured but rare

homozygous uncommon genotype (RGS9).

RESULTS

GWAS study design.

To discover genetic determinants of pulmonary tuberculosis (PTB) susceptibility in Brazil, we

examined genotypes by low-pass whole genome sequencing (lpWGS) with imputation (N =

6,944,453 SNPs with minor allele frequency [MAF] > 5%) in culture-confirmed PTB cases and

close contact controls from the RePORT-Brazil cohort (**Figure 1A, Figure S1**). We performed two

complementary analyses: a full cohort risk-adjusted design (N = 947 cases, 1807 controls) to

maximize statistical power to detect smaller effects and a case-control strategy (N = 578 cases,

241 controls) to reduce PTB risk factor variance in order to detect less biased causal effects.

When compared to controls in the full cohort (**Table 1**), PTB cases had a higher male frequency

(67% cases vs 41% controls, P = 1E-37), were older (38 ± 14 vs 33 ± 19, P = 2E-14), had lower

BMI (21 ± 3.5 vs 25 ± 6.5, P = 7E-71), and had higher prevalence of tobacco use (52% vs 27%, P =

8E-40), HIV (20% vs 2%, P = 1E-53), and DM (23% vs 5%, P = 5E-45). Among PLWH, PTB cases

had higher usage of ART (41% vs 0%) and lower CD4 counts (218 ± 225 vs 467 ± 340, P = 1E-06)

than controls. Also, 30% of controls received TB infection (TBI) treatment while on study (190 ±

84 days). The case-control subset fully controlled for HIV and DM (0%) and was more balanced

for age (P = 0.07) and TBI treatment (maximum 30 days in controls) (**Table 1**).

GWAS SNP-level primary results with high-pass WGS confirmation.

Previous TB GWAS studies commonly corrected for age, sex, and genetic relatedness (ancestry

PCs and/or kinship). To assess whether to include additional covariates, we tested GWAS

models on a random sample of 10,000 SNPs in the full cohort for improved fit as measured by

reductions in the Akaike information criterion (AIC). We selected a full cohort model adjusting

for ancestry, sex, age, smoking, HIV, DM, and kinship (equation (1)). The case-control subset

was modeled for a comparable model removing PTB risk covariates (HIV, DM) that were absent

in this subset. The full cohort and case-control analyses had an expected quantile-quantile (QQ)

trend with the majority of SNPs following a one-to-one ratio and significant SNPs deviating from

this trend with low genomic inflation factors (λ = 0.985 and 0.994, respectively) (**Figure S4**). In

the full cohort model, 68 low-pass WGS genotyped SNPs were significantly associated with PTB

disease (P < 5E-08) and an additional 686 SNPs were suggestive (P < 5E-05) (**Table S1**). In the

case-control subset, no SNPs reached significance but 164 were suggestive (P < 5E-05) (**Table

S1**).

A random subset of 50 participants (25 PTB cases and 25 controls) were assessed using 30X

high-pass whole genome sequencing (hpWGS) to confirm lpWGS imputation results. Selected

individuals represented the overall genetic diversity of the cohort as seen in PCA (**Figure S5A**).

Of the 49.5 million imputed lpWGS SNPs, 31% were called in at least 1 participant in the high-

pass subset (**Figure S5B**). The majority of lpWGS SNPs that were called in hpWGS were high-

quality, including > 90% (28% of all SNPs) with imputation scores > 0.6. In contrast, nearly half

of lpWGS SNPs that were not called in hpWGS failed imputation quality filtering (score < 0.6),

indicating poor-quality in both data sets. Among the 15.5 million lpWGS SNPs called in all 50

high-pass participants, concordance was 74 ± 26% between high-pass and imputed low-pass

data (**Figure S5C**, **Table S3**), which is slightly below the GLIMPSE2 reported values for 1X

imputed data (r = 0.8) [42]. Among imputation and MAF pass-filter GWAS-significant SNPs (N =

68), there was lower coverage (50%) (**Figure S5D**) and lower concordance (57 ± 29%) compared

to the high pass data (**Figure S5E**). Specifically among significant low-pass SNPs, 34 were not

called in high-pass data, 19 had concordance ≥ 60%, and 15 had concordance < 60% (**Figure**

S5F, **Table S3**). Significant SNPs with concordance ≥ 60% were used in further analyses. In the

full cohort, 19 concordant SNPs were significant (P < 5E-08) and an additional 238 were

suggestive (P < 5E-05) in GWAS models (**Figure 1B**, **Table 2**). The case-control subset had 64

suggestive concordant SNPs, none of which overlapped with full cohort significant or suggestive

SNPs (**Figure 1B**, **Table 2**). Significant SNPs were spread across the genome, including 11

different chromosomes (**Figure 1C, D**).

400   Utilizing the 2,527,008 concordant SNPs across the entire lpWGS data set and a subset

of 1020 unrelated individuals, we estimated heritability by Genome-wide Complex Trait

Analysis (GCTA). GCTA found that 47.7 ± 23.8 s.e. % of the variance in PTB disease in this cohort

can be explained by genetic factors when corrected for ancestry, age, sex, and PTB risk

covariates (**Table S4**). Given the low rate of PTB in the population relative to participants used

in the GCTA analysis (0.06 vs 42%), the scaled heritability was estimated to be 15.8 ± 7.9%.

When PTB risk covariates were not incorporated (smoking, HIV, DM), heritability estimates

were lower at 18.2 ± 22.5% overall and 7.3 ± 7.5% scaled for population prevalence. Together,

these data suggest PTB progression in Brazil is partially genetically regulated with high

heritability and that 19 concordant SNPs were associated with PTB in the full cohort analysis.

Impact of clinical covariate correction.

To assess the impact of PTB risk co-variate inclusion in our study design, we performed analyses with a "standard" GWAS model including age, sex, ancestry PCs, and kinship as well as targeted PTB models lacking one of the PTB risk covariates included in the final full cohort model (HIV, DM, smoking). While P-values were correlated between the model with all PTB risk covariates and the "standard" model with no PTB risk covariates (Pearson R = 0.83, P < 2.2E-16), the "standard" model identified only 3 significant SNPs, which fully overlapped with the full model's results (P < 5E-08, **Figure 3A**). Thus, accounting for PTB risk factors yielded 16 more significant SNPs without loss of any signal found with a "standard" GWAS model. Among the 19 concordant SNPs significant in the full cohort final model, the majority were detected when at least 2 out of 3 PTB risks were accounted for (**Figure 3B**). Notably, the addition of HIV and/or DM resulted in the greatest increases in significant SNPs detected. Smoking had less impact on significant SNP detection, though 2 SNPs were identified only when all three risk covariates were included. Thus, correction for PTB risk covariates improved model fit (**Figure S2G,H**) and retained statistical power to detect associations with PTB in the full cohort (**Figure 3**).

SNP functional and genomic annotation.

We next mapped the significant SNPs to assess their genomic and functional features. We first assessed LD patterns surrounding significant lead SNPs. We assessed lower frequency SNPs (> 1% MAF) within 10 kb of significant concordant GWAS SNPs for linkage disequilibrium (LD R^2) with the lead SNP (**Table S1**). ZNF717 was the only SNP with surrounding SNPs with high LD and

432 low P-values (**Figure 2**). In contrast, the remaining significant SNPs did not have clustering due

433 to limited concordant calls and/or low LD in the region.

435 The majority of significant, concordant SNPs (17 of 19 SNPs) were annotated within genes or

436 within 50 kb cis of genes, including protein-coding and RNA genes (lncRNA, snRNA, snoRNA) as

437 well as pseudogenes (**Figure 1E**, **Table S5**). In total, 5 significant concordant SNPs mapped to 5

438 protein-coding gene transcripts and 7 SNPs were 50 kb cis to 6 protein-coding genes (**Table 2**).

439 Among these 11 genes, there was minimal gene set enrichment within the Hallmark, canonical

440 pathways, or gene ontology databases (FDR < 0.3, overlap > 1, **Table S6**). These included

441 Reactome RNA polymerase II transcription (MAML3, ZNF717) and Wikipathways VEGFA-

442 VEGFR2 signaling pathway (ATF4, CGNL1, CYP2C8). None of the 12 protein-coding concordant

443 SNPs were significant predictors of a sex, age, smoking, HIV, or DM (**Table S1**), further

444 supporting their association with PTB after correction for these clinical covariates. Further

445 analyses focus on the 12 protein-coding region SNPs to enrich for potentially causative

446 relationships to PTB disease.

448 *Single-cell eQTL analysis.*

449 To assess whether significant concordant SNPs were associated with cis gene expression, we

450 examined a PBMC single-cell RNAseq dataset from the same cohort. SNPs significantly

451 associated with PTB disease (P < 5e-08), concordant in high-pass data (> 60%), and annotated to

452 protein-coding genes (N = 12) were modeled against expression of their annotated genes. In

453 total, 58 participants were present in both datasets; this subset was 36 ± 18 years old, 34%

454 male (N = 20), and had similar PTB risk factors as the larger cohort including 25 ± 6.6 BMI, 10%

455 DM (N = 6), 26% tobacco users (N = 15), and no persons living with HIV (PLWH). In total, 9

456 GWAS-significant concordant SNPs were mapped to 8 protein-coding genes expressed in at

457 least one cell type in single-cell RNA-seq. CGNL1, CYP2C8, and MPPED1 were not expressed in

458 any cell type; thus, their associated SNPs were not modeled in sceQTL analysis. Among the 32

459 annotated cell types (**Figure S6A**), all expressed at least one gene of interest, and genes of

460 interest were generally expressed in the majority of cell types with a wide range of expression

461 levels (**Figure S6B**). The exception to this was CACNA1I (calcium voltage-gated channel subunit

462 alpha), which were expressed in only 12 cell types.

464 Overall, 9 unique SNP-gene-cell models were significant eQTLs (FDR < 0.05, **Table S2**). These

465 represented 7 SNPs, 4 genes, and 7 cell types (**Figure 4A**). Specifically, SNPs associated with a

466 higher risk of PTB in the clinical GWAS were associated with lower ZNF717 (zinc finger protein)

467 expression in classical and monocytes and naïve B cells (**Figure 4B**). For monocytes, these

468 effects were seen for the lead SNP (3:75816280:A:T) as well as two additional SNPs in LD in this

469 region (**Figure S7A**). Co-localization was observed for ZNF717 GWAS SNPs and sceQTLs in

470 monocytes but less so in B cells, which may indicate indirect effects or a different causal variant

471 in this cell type (**Figure S7A**). Among the ZNF717-significant SNPs, only one (3:75816219:T:G)

472 was present on any previously employed SNP arrays (Illumina MEGA[EX] , **Table S7**). In addition,

473 an intronic COX10 (cytochrome C oxidase assembly factor) SNP was significantly associated with

474 higher gene expression in B cells expressing IFN stimulated genes (isg) (**Figure 4C**). Despite

475 sparse genotyping in this region, a more highly significant SNP in LD with several suggestive

SNPs was found upstream (**Figure S7B**), thus indicating that the GWAS-significant SNP may not

be causally associated with gene expression. An intronic RGS9 (regulator of G protein signaling)

SNP was associated with higher gene expression in CD56-bright natural killer cells (**Figure 4D**)

with some GWAS colocalization but no LD with the sceQTL SNP (**Figure S7C**). This effect was

present in either an additive (FDR = 0.035) or dominant model (FDR = 0.025), thus ensuring that

the effect was not driven by the single homozygous uncommon individual. Finally, an intronic

MAML3 (mastermind-like transcriptional coactivator) SNP previously identified on the

LIMAArray (**Table S7**) significantly associated with lower expression of this gene in stressed

myeloid cells and higher expression in CD8+ and other T cells (**Figure 4E**). Minimal nearby SNPs

were successfully genotyped in this region, which resulted in no apparent LD structure though

some co-localization was apparent due to the closest surrounding SNPs not significantly

associated with gene expression (**Figure S7D**). Together, these expression studies suggest that

several SNPs were cell-specific eQTLs with directionality that informs biological models of PTB

pathogenesis.

DISCUSSION

We used a genome wide association study (GWAS) to discover genetic variants associated with

pulmonary tuberculosis (PTB) in Brazil with three important study design features: inclusion of

extended epidemiologic risk factors in case-control definitions, genotyping with imputed low-

pass whole genome sequencing (lpWGS) to capture more comprehensive population-specific

variants, and the assessment of the functional significance of candidate genetic variants with

single-cell eQTL (sceQTL) analysis in the same cohort. We discovered several genetic variants

associated with PTB with genome-wide level significance and associated function in cell-specific

sceQTLs.

To gain insight into genetic regulation of susceptibility to PTB, we examined high-confidence

imputed lpWGS SNPs that were associated with PTB disease, concordant in high-pass WGS

(hpWGS), mapped to protein-coding genes, and expressed in a matched single-cell RNA-seq

experiment. Notably, zinc finger protein 717 (ZNF717) SNPs were associated with gene

expression in monocytes or B cells. This region was the only one to display a characteristic

GWAS "build-up" of signal among SNPs with lower P-values and high linkage disequilibrium

(LD). Importantly, only one of these SNPs (rs113392015) was present on any commonly used

SNP array. ZNF717 encodes a Kruppel-associated box (KRAB) zinc-finger protein, which binds

DNA and has predicted roles in regulation of transcription, but no published experimental

studies of its function. Here, multiple ZNF717 SNPs were sceQTLs associated with decreased

expression in classical monotypes while a single SNP was associated with increased expression

in naïve and interferon stimulated gene (ISG) expressing B cells. Together, these data suggest

that genetic regulation of ZNF717 across multiple loci impacts corresponding gene expression

and is associated with increased susceptibility to PTB.

Additionally, an intronic mastermind-like transcriptional coactivator 3 (MAML3) SNP was

associated with PTB risk and gene expression in multiple cell populations. The MAML3 SNP was

associated with decreased expression of MAML3 expression in stressed myeloid cells but

increased expression in CD8+ cytotoxic and other T cells. MAML3 is a transcription coactivator

involved in positive regulation of transcription, particularly Notch signaling. Notch pathways

have been implicated in PTB disease including T cell cytokine production [43], Th1/Th2 balance [44],

and apoptosis in response to *Mycobacterium tuberculosis* (Mtb) antigen [45]. Thus, genetic

regulation of Notch through MAML3 may contribute to PTB risk. Also, an intronic Regulator of G

protein signaling 9 (RGS9) SNP was associated with increased PTB risk and RGS9 gene

expression in CD56-bright natural killer (NK) cells. While the canonical role of RGS9 is regulation

of neuronal G protein signaling pathways [46,47], it has been linked to a tissue resident-like

phenotype in NK cells [48]. In particular, CD56-bright NK cells are characterized by higher

interferon-gamma (IFNG), tumor necrosis factor-beta (TNFB), interleukin-10 (IL10), and IL12

production in response to monocyte-derived cytokines when compared to their CD56-dim

counterparts [49]. Thus, these NK-derived cytokines may provide an important innate immune

response to PTB downstream of primary monocyte infection. These data suggest a possible

genetic regulator of the tissue resident-like NK phenotype through RGS9. Overall, the

combination of GWAS and sceQTL datasets in the same cohort enables rapid screening of

GWAS SNPs for those most likely to impact PTB disease through transcriptomic outcomes. The

single-cell approach further facilitates detailed identification of the involved cell types as well as

directionality and magnitude of effects.

Our study had several limitations. First, although one distinguishing feature of this study was its

use of unbiased genome-wide genotyping with lpWGS, imputation discrepancies did exist

between lpWGS and hpWGS, even among SNPs that passed lpWGS imputation quality and

minor allele frequency (MAF) filtering. This may indicate genomic regions prone to low quality

sequencing and/or imputation that should be excluded in future studies. However, testing with

additional populations and reference data sets is necessary to confirm these regions,

particularly given the sparsity of Brazilian individuals in current references. Nevertheless, this

method yielded millions of SNPs not represented by current or past SNP arrays, and overall,

imputed lpWGS genotype calls were highly concordant with hpWGS. Second, this study cohort

displayed diverse ethnic and geographic backgrounds [50] as well as variability in a number of

known PTB risk factors. Traditionally, GWAS correct for age, sex, and ancestry as well as often

exclude individuals with known risk factors. Here, we have shown through statistical

assessment that exclusion was not necessary, and many factors can be accounted for as model

covariates. This preserved sample size, and thus statistical power, which would otherwise be

reduced in case-control designs. Specifically, PTB risk factors including HIV, DM, and smoking

improved model fit as well as increased PTB signal despite reduced degrees of freedom in the

more complex statistical model. The more controlled, smaller case-control study failed to

identify these statistically significant SNPs, likely as a result of reduced power. This underscores

the importance of these factors in PTB risk assessment and may contribute to the lack of

reproducibility among TB GWAS that did not account for similar risk factors. Third, the sample

size of this PTB GWAS did not allow for the detection of rare variants (MAF < 5%) and was

under-powered to detect SNPs with small effect sizes. Finally, despite advances in design and

methodology, this GWAS failed to identify PTB-associated SNPs of significance described in

prior GWAS, even SNPs present on prior SNP arrays. This is a common feature among TB GWAS

and may indicate an abundance of population-specific genetic risk factors. Mtb has co-evolved

with humans for thousands of years, and there is considerable Mtb strain variability worldwide

[51]. Thus, population-specific SNPs relevant to PTB disease risk are likely present, and unbiased

genotyping across multiple populations will be necessary to identify population-spanning SNPs.

In summary, this PTB GWAS identified 12 protein-coding loci associated with PTB disease and

linked seven of these SNPs to potential functional consequences through sceQTL analysis.

These findings provide new insights into genetic risks of PTB in the highly admixed Brazilian

population. While no overlap was found between this and prior TB GWAS, future studies

employing lpWGS may yield population-spanning SNPs not previously measured across

populations due to the limitations of prior SNP arrays. Thus, this study provides important

groundwork for both lpWGS methods and the assessment of genetic risks for PTB.

DATA AVAILABILITY

Sequence files for this project are available in the database of Genotypes and Phenotypes

(dbGaP) [in progress]. All scripts associated with this project can be found in

https://github.com/hawn-lab/ReporTB_GWAS_public.

ACKNOWLEDGEMENTS

We thank the individual study participants of the Regional Prospective Observational Research

in Tuberculosis (RePORT)-Brazil consortium, study coordinators, and the clinical and research

staff at all sites.

FUNDING

This work was supported by NIH ROI AI147765 (BBA, TRS, TRH), R01 AI20790 (VCR, TRS),

U01AI172064 (BBA, TRS), U01 AI069923, and CRDF Global DAA9-19-65383-1 (TRH). ALK, BBA,

MCS, and VCR are fellows from the National Council for Scientific and Technological

Development (CNPq), Brazil.

FINANCIAL DISCLOSURES

KADM reports consulting fees for bioinformatic tool development from Seattle BioSoftware and

EuropaDX. All other authors report no competing financial interests.

AUTHOR CONTRIBUTIONS

Study design (KADM, BBA, SAK, PFR, GA, SAM, TRS, TRH), study supervision (BBA, SAK, TRS,

TRH), program management (MCF), study enrollment and data collection (AMSA, MCS, ALK,

VCR), sample collection and processing (AMSA, FAR, JMCA, RDG), data cleaning (KADM, JDS,

RDG), single cell annotation (JDS, JMO, JPA, HIN), GWAS and sceQTL statistics (KADM), and

primary manuscript writing (KADM, TRH). All authors reviewed and approved the final

manuscript.

The Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil Consortium

<u>Salvador, BA, Brazil</u>

Laboratório de Pesquisa Clínica e Translacional, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz (FIOCRUZ): Mariana Araújo-Pereira

Instituto de Pesquisa Clínica e Translacional, Medicina Zarns, Clariens Educação: Mariana Araújo-Pereira, Artur T L Queiroz

Instituto Brasileiro para Investigação da Tuberculose, Fundação José Silveira: Michael Rocha, Vanessa Nascimento, Victor Porfirio

<u>Rio de Janeiro, RJ, Brazil</u>

Programa Acadêmico de Tuberculose da Faculdade de Medicina, Universidade Federal do Rio de Janeiro: Adriana Moreira, André Luiz Bezerra, Anna Cristina Carvalho

Laboratório de Pesquisa Clínica em Micobacteriose, Instituto Nacional de Infectologia Evandro Chagas (FIOCRUZ): Adriano Gomes Silva, Aline Benjamin, Quezia Medeiros, Flavia M Sant'Anna

Secretaria Municipal de Saúde do Rio De Janeiro e Clínica Da Família Rinaldo Delamare: Solange Cavalcante, Betina Durovni, Jamile Garcia, João Marine

<u>Manaus, AM, Brazil</u>

Fundação de Medicina Tropical Dr. Heitor Vieira Dourado do Amazonas: Allyson G Costa, Brenda Carvalho, Alexandra Brito, Leandro Garcia, Renata Spener

624   <u>Nashville, TN, USA</u>

625   Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center:

626   Angela Jones, Hilary V Riley, Cody Staats, Megan Turner

REFERENCES

1. Rosain, J. *et al.* Mendelian susceptibility to mycobacterial disease: 2014–2018 update. *Immunol Cell Biol* **97**, 360–367 (2019).
2. Hill, A. V. S. The Genomics and Genetics of Human Infectious Disease Susceptibility. *Annu Rev Genomics Hum Genet* **2**, 373–400 (2001).
3. Luo, Y. *et al.* Early progression to active tuberculosis is a highly heritable trait driven by 3q23 in Peruvians. *Nat Commun* **10**, 3765 (2019).
4. Sveinbjornsson, G. *et al.* HLA class II sequence variants influence tuberculosis risk in populations of European ancestry. *Nat Genet* **48**, 318–322 (2016).
5. Png, E. *et al.* A genome wide association study of pulmonary tuberculosis susceptibility in Indonesians. *BMC Med Genet* **13**, 5 (2012).
6. Thye, T. *et al.* Common variants at 11p13 are associated with susceptibility to tuberculosis. *Nat Genet* **44**, 257–259 (2012).
7. Thye, T. *et al.* Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2. *Nat Genet* **42**, 739–741 (2010).
8. Grant, A. V *et al.* A genome-wide association study of pulmonary tuberculosis in Morocco. *Hum Genet* **135**, 299–307 (2016).
9. Chimusa, E. R. *et al.* Genome-wide association study of ancestry-specific TB risk in the South African Coloured population. *Hum Mol Genet* **23**, 796–809 (2014).
10. Bai, H. *et al.* Genome-wide association study of tuberculosis in the western Chinese Han and Tibetan population. *MedComm (Beijing)* **4**, e250 (2023).
11. Zheng, R. *et al.* Genome-wide association study identifies two risk loci for tuberculosis in Han Chinese. *Nat Commun* **9**, 4072 (2018).
12. Mahasirimongkol, S. *et al.* Genome-wide association studies of tuberculosis in Asians identify distinct at-risk locus for young tuberculosis. *J Hum Genet* **57**, 363–367 (2012).
13. Rubinacci, S., Ribeiro, D. M., Hofmeister, R. J. & Delaneau, O. Efficient phasing and imputation of low-coverage sequencing data using large reference panels. *Nat Genet* **53**, 120–126 (2021).
14. Arriaga, M. B. *et al.* Novel stepwise approach to assess representativeness of a large multicenter observational cohort of tuberculosis patients: The example of RePORT Brazil. *International Journal of Infectious Diseases* **103**, 110–118 (2021).
15. Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**, 68–74 (2015).
16. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* **81**, 559–575 (2007).
17. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* **4**, (2015).
18. R Core Team. R: A language and environment for statistical computing. Preprint at https://www.r-project.org/ (2023).
19. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies. *Bioinformatics* **26**, 2867–2873 (2010).
20. Zheng, X. *et al.* A high-performance computing toolset for relatedness and principal component analysis of SNP data. *Bioinformatics* **28**, 3326–3328 (2012).

21. Conomos, M. P., Miller, M. B. & Thornton, T. A. Robust Inference of Population
Structure for Ancestry Prediction and Correction of Stratification in the Presence of
Relatedness. *Genet Epidemiol* **39**, 276–293 (2015).

22. Gogarten, S. M. *et al.* Genetic association testing using the GENESIS R/Bioconductor
package. *Bioinformatics* **35**, 5346–5348 (2019).

23. Conomos, M. P., Reiner, A. P., Weir, B. S. & Thornton, T. A. Model-free Estimation of
Recent Genetic Relatedness. *The American Journal of Human Genetics* **98**, 127–148
(2016).

24. Chen, H., Conomos, M. & Pham, D. GMMAT: Generalized Linear Mixed Model
Association Tests. Preprint at (2023).

25. Dolgalev, I. msigdbr: MSigDB Gene Sets for Multiple Organisms in a Tidy Data Format.
Preprint at https://cran.r-project.org/package=msigdbr (2019).

26. Benson, B., Dill-McFarland, K. A., Cox, M. S. & Janczyk, T. SEARchways: gene set and
pathway enrichment. Preprint at https://doi.org/10.5281/zenodo.13145502 (2024).

27. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: A Tool for Genome-wide
Complex Trait Analysis. *The American Journal of Human Genetics* **88**, 76–82 (2011).

28. Yang, J. *et al.* Common SNPs explain a large proportion of the heritability for human
height. *Nat Genet* **42**, 565–569 (2010).

29. Silva Júnior, J. N. de B. *et al.* Trends in tuberculosis incidence and mortality coefficients
in Brazil, 2011–2019: analysis by inflection points. *Revista Panamericana de Salud*
Pública **47**, 1 (2023).

30. Dill-McFarland, K. A., Benson, B. & Segnitz, R. M. SEAsnake: a snakemake pipeline for
processing RNA-seq fastq to counts. *Zenodo* (2024) doi:10.5281/zenodo.11646755.

31. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21
(2013).

32. Danecek, P. *et al.* Twelve years of SAMtools and BCFtools. *Gigascience* **10**, giab008
(2021).

33. Hinrichs, A. S. *et al.* The UCSC Genome Browser Database: update 2006. *Nucleic Acids*
Res **34**, D590–D598 (2006).

34. Zheng, G. X. Y. *et al.* Massively parallel digital transcriptional profiling of single cells.
Nat Commun **8**, 14049 (2017).

35. Linderman, G. C. *et al.* Zero-preserving imputation of single-cell RNA-seq data. *Nat*
Commun **13**, 192 (2022).

36. Korsunsky, I. *et al.* Fast, sensitive and accurate integration of single-cell data with
Harmony. *Nat Methods* **16**, 1289–1296 (2019).

37. Hao, Y. *et al.* Dictionary learning for integrative, multimodal and scalable single-cell
analysis. *Nat Biotechnol* **42**, 293–304 (2024).

38. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for
differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–
140 (2010).

39. Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing
and microarray studies. *Nucleic Acids Res* **43**, e47 (2015).

40. Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock linear
model analysis tools for RNA-seq read counts. *Genome Biol* **15**, R29 (2014).

41. Dill-McFarland, K. A. *et al.* Kimma: flexible linear mixed effects modeling with kinship
covariance for RNA-seq data. *Bioinformatics* **39**, btad279 (2023).

42.   Rubinacci, S., Hofmeister, R. J., Sousa da Mota, B. & Delaneau, O. Imputation of low-
717   coverage sequencing data from 150,119 UK Biobank genomes. *Nat Genet* **55**, 1088–1090
718   (2023).
719   43.   Schaller, M. A., Allen, R. M., Kimura, S., Day, C. L. & Kunkel, S. L. Systemic
720   Expression of Notch Ligand Delta-Like 4 during Mycobacterial Infection Alters the T Cell
721   Immune Response. *Front Immunol* **7**, (2016).
722   44.   Li, Q. *et al.* Down-regulation of Notch signaling pathway reverses the Th1/Th2 imbalance
723   in tuberculosis patients. *Int Immunopharmacol* **54**, 24–32 (2018).
724   45.   Palaga, T. *et al.* Notch signaling regulates expression of Mcl-1 and apoptosis in PPD-
725   treated macrophages. *Cell Mol Immunol* **10**, 444–452 (2013).
726   46.   Chen, C.-K. J. Chapter Three - RGS Protein Regulation of Phototransduction. in *Progress*
727   *in Molecular Biology and Translational Science* (ed. Fisher, R. A.) vol. 133 31–45
728   (Academic Press, 2015).
729   47.   Masuho, I., Wakasugi-Masuho, H., Posokhova, E. N., Patton, J. R. & Martemyanov, K. A.
730   Type 5 G Protein β Subunit (Gβ5) Controls the Interaction of Regulator of G Protein
731   Signaling 9 (RGS9) with Membrane Anchors*. *Journal of Biological Chemistry* **286**,
732   21806–21813 (2011).
733   48.   Brownlie, D. *et al.* Expansions of adaptive-like NK cells with a tissue-resident phenotype
734   in human lung and blood. *Proceedings of the National Academy of Sciences* **118**,
735   e2016580118 (2021).
736   49.   Cooper, M. A. *et al.* Human natural killer cells: a unique innate immunoregulatory role for
737   the CD56bright subset. *Blood* **97**, 3146–3151 (2001).
738   50.   Piekos, J. A. *et al.* Genetic ancestry proportion influences risk of adverse events from
739   tuberculosis treatment in Brazil. *medRxiv* 2024.08.29.24312595 (2024)
740   doi:10.1101/2024.08.29.24312595.
741   51.   Brites, D. & Gagneux, S. The Nature and Evolution of Genomic Diversity in the
742   Mycobacterium tuberculosis Complex. in *Strain Variation in the Mycobacterium*
743   *tuberculosis Complex: Its Role in Biology, Epidemiology and Control* (ed. Gagneux, S.)
744   1–26 (Springer International Publishing, Cham, 2017). doi:10.1007/978-3-319-64371-7_1.
745

Table 1. Cohort demographics of Brazil Regional Prospective Observational Research in TB

(RePORT) GWAS

		Full cohort			Case-control cohort		
		Close contacts	TB cases	P[a]	Close contacts	TB cases	P[a]
	N	1807	947		241	578	
Clinical	Age < 5 yrs (N)	33 ± 19 94	38 ± 14 0	2E-14	38 ± 17 2	36 ± 14 0	7E-02
	Sex (male)	738 (41%)	631 (67%)	1E-37	83 (34%)	367 (64%)	5E-14

	Race
	   Brown
	   Black
	   White
	   Other
		1078 (60%)
		360 (20%)
		350 (20%)
		19 (1%)
			489 (52%)
			243 (26%)
			195 (21%)
			20 (2%)
				3E-04	130 (54%)
					79 (33%)
					28 (12%)
					4 (2%)
						261 (45%)
						177 (31%)
						129 (22%)
						11 (2%)
							8E-03

TB risk	BMI	25 ± 6.5	21 ± 3.5	7E-71	26 ± 5.8	20 ± 3.1	8E-49
	Tobacco use (current, past)	478 (27%)	491 (52%)	8E-40	75 (31%)	279 (48%)	9E-06
	Diabetes mellitus (DM) Hemoglobin A1C (HbA1c)[b]	96 (5%) *NA*	221 (23%) 6.4 ± 2.0%	5E-45	0	0	

	HIV
	   Anti-retroviral therapy (ART)
	   CD4 counts [min, max]
		44 (2%)
		0
		467 [108, 1561]
			186 (20%)
			77 (41%)
			218 [6, 1092]
				1E-53
				
				1E-06
					0
					
					NA
						0
						
						NA	

	LTBI treatment Cumulative treatment (days)	437 (30%) 190 ± 84	0		9 (3%) 15 ± 10	0	

[a] Numeric variable compared using Wilcoxon test. Categorical variables compared using Chi-squared. [b] DM was self-reported in controls and determined by HgA1c in cases. NA: not applicable

Table 2. GWAS-level significant SNPs annotated to protein-coding genes [a]

| | snpID | rsID | Full cohort | | | | | Case-control cohort | | Impute | hpWGS | Annotation | | sceQTL[b] |
			P	OR	MAF control	MAF case	P other models	P	OR	Score	Match (%)	Gene	Detail / kb to gene	Cell type FDR < 0.05
Intragenic	4:139801643:G:T	rs13114088	2.6E-09	2.2	5.5	8.8		0.036	1.6	0.65	72	MAML3	Intron 2	sMyeloid, c tCD8
	15:57418934:T:C	rs56380268	5.4E-09	2.2	4.8	7.6		0.35	1.2	0.66	86	CGNL1	Intron 1	*nd*
	17:14155330:A:G	rs34369729	3.5E-08	2.1	5.1	8.3		0.43	1.2	0.64	74	COX10	Intron 4	isgB
	17:65130128:A:T	rs9303479	1.0E-10	2.4	5.1	8.6		0.085	1.5	0.65	84	RGS9	Intron 1	NK-CD56+
	22:43432220:G:A	rs1458265905	2.9E-09	2.2	5.4	8.9		0.0021	2.1	0.69	76	MPPED1	Intron 2	*nd*
Cis up to 50 kb	3:75816211:A:G	rs111435847	3.4E-10	2.4	4.3	7.6		0.016	1.8	0.83	88	ZNF717	30.6	
	3:75816219:T:G	rs113392015	1.4E-10	2.4	4.5	7.9		0.022	1.7	0.84	88	ZNF717	30.6	cMono-2
	3:75816280:A:T	rs78962383	6.2E-11	2.4	4.7	8.3		0.025	1.7	0.81	80	ZNF717	30.7	
	3:75816310:C:A	rs113424442	3.4E-10	2.4	4.7	8.0		0.054	1.6	0.71	76	ZNF717	30.7	
	3:75816342:A:C	rs113386032	3.2E-08	2.2	4.4	6.9		0.088	1.5	0.80	84	ZNF717	30.8	nB
	10:95079377:G:A	rs200480013	1.8E-11	2.3	5.4	9.4		0.015	1.7	0.79	66	CYP2C8	9.9	
	22:39566026:A:T	rs199749312	2.5E-10	2.5	4.2	7.5		0.016	1.8	0.81	82	ATF4	43.3	
												CACNA1I	4.7	*nd*
												MIEF1	47.9	
												RPS19BP1	33.3	

[a] Details on all significant SNPs can be found in **Table S5**. SNPs in this table were derived from imputed low pass WGS dataset, had > 60% concordance with high pass WGS, and were annotated to protein-coding genes. [b] sMyeloid: stressed myeloid cell, oT: other T cell, tCD8: T cell CD8+ cytotoxic, isgB: B cell expressing IFN stimulated genes, cMono: classical monocyte, nB: B cell naïve, *nd*: Not detected in single cell expression. MAF: minor allele frequency, OR: odds ratio, hpWGS: high-pass whole genome sequencing, sceQTL: single-cell expression quantitative trait loci

Figure 1. SNPs associated with TB in Brazil GWAS. SNPs at > 5% MAF and verified > 60%

concordant in high-pass data are included. (A) Study design and analysis. Additional details can

be found in Figure S1. Created with biorender.com. (B) In the full cohort, significant (green, P <

5E-8) and suggestive SNPs (yellow, P < 5E-5) did not overlap with any suggestive SNPs identified

in the case-control cohort (blue, P < 5E-5). No SNPs were significant in the case-control cohort

(grey, P < 5E-8). Manhattan plots for the (C) full cohort and (D) case-control subset. Concordant

genotypes are colored if significant or suggestive in either the full cohort or case-control with

colors as in (B). For nonsignificant SNPs, alternating odd and even numbered chromosomes are

shaded in greys. (E) Gene-level annotations of concordant significant SNPs. Genes are grouped

by their closest annotation within a gene or within 50 kb cis of a gene. SNP annotations are

colored by protein-coding, pseudogene, RNA (lncRNA, snRNA, snoRNA), and no annotation

groups.

Figure 2. Genomic regions of significant protein-coding SNPs in the full cohort. SNPs significant

for TB progression in the full cohort as well as > 60% concordant with high-pass sequencing

were selected. SNPs were annotated to protein-coding genes (A) intragenic and (B) cis up to 50

kb. Manhattan plots with concordant SNPs at > 1% MAF and +/- 10 kb from these SNPs are

shown with color indicating linkage disequilibrium (LD R^2) with lead SNPs, which are highlighted

as red diamonds. Gene annotations are noted on the x-axis.

-

Figure 3. GWAS model impact of correcting for TB risk covariates. The primary full cohort

model for TB progressions corrected for ancestry PCs, genetic kinship, age, sex, smoking, HIV,

and DM (all covariates). A second, simplified model without TB risk covariates (smoking, HIV,

DM) was then applied to the same data. Only SNPs > 5% MAF and > 60% concordance in the

high-pass data are shown. (A) Pearson correlation of P-values for all SNPs in the two models.

The red line indicates a 1:1 fit. Dashed lines and colored points indicate model significance (P <

5E-8), and there were no SNPs significant in only the no TB risk covariate model. (B) Impacts of

individual TB risk covariates. Leave-one-out models were applied to the 19 SNPs concordant in

high-pass and significant in the full cohort model with all covariates (grey box). Significant SNPs

in each model lacking one TB risk covariates are totaled in the Venn diagram with 2 SNPs

outside the Venn, indicating significance only when all three TB risk covariates are included in

the model.

Figure 4. **Single cell cis-expression quantitative loci (sceQTL) among TB GWAS significant SNPs.**

GWAS significant concordant SNPs were mapped 50 kb cis to protein-coding genes that were expressed in single-cell data. Gene expression was modeled against corresponding mapped SNPs. (A) Volcano plot of sceQTLs. Color and shape indicate significant sceQTL cell populations (FDR < 0.05). Labels note the gene annotation for significant SNPs with bracketed numbers indicating the total number of significant SNPs when > 1. (B) ZNF717, (C) COX10, (D) RGS9, and (E) MAML3 sceQTLs. Pseudobulk normalized counts per million (CPM) per donor in sceQTLs

with SNPs significant in GWAS (P < 5E-8). Genotypes are represented as the number of alternate

alleles (0: grey, 1 or 2: black) with SNPs identified by chromosome:position:reference:alternate.

Trend lines represent linear models with positive (red) and negative (blue) effects of the

alternate allele. cMono-2: Monocyte classical cluster 2, isgB: B cell expressing IFN stimulated

genes, nB: B cell naïve, NK-CD56++: natural killer cell CD56 bright, oT: T cell other, sMyeloid:

myeloid cell stressed, tCD8: T cell CD8+ cytotoxic